Efficient Expression of Functionally Active Aflibercept with Designed N-glycans.
Fc fusion
aflibercept
anti VEGF
glycan engineering
glycosylation
plant expression
Journal
Antibodies (Basel, Switzerland)
ISSN: 2073-4468
Titre abrégé: Antibodies (Basel)
Pays: Switzerland
ID NLM: 101587489
Informations de publication
Date de publication:
07 Apr 2024
07 Apr 2024
Historique:
received:
14
12
2023
revised:
05
03
2024
accepted:
27
03
2024
medline:
23
4
2024
pubmed:
23
4
2024
entrez:
23
4
2024
Statut:
epublish
Résumé
Aflibercept is a therapeutic recombinant fusion protein comprising extracellular domains of human vascular endothelial growth factor receptors (VEGFRs) and IgG1-Fc. It is a highly glycosylated protein with five N-glycosylation sites that might impact it structurally and/or functionally. Aflibercept is produced in mammalian cells and exhibits large glycan heterogeneity, which hampers glycan-associated investigations. Here, we report the expression of aflibercept in a plant-based system with targeted N-glycosylation profiles.
Identifiants
pubmed: 38651409
pii: antib13020029
doi: 10.3390/antib13020029
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : FWF Austrian Science Fund
ID : I 4328-B
Organisme : FWF Austrian Science Fund
ID : I 3721-B30
Organisme : Austrian Research Promotion Agency
ID : COMET-Competence Centers for Excellent Technologies